Serum asprosin levels and bariatric surgery outcomes in obese adults - International Journal of Obesity
- ️Yeh, Ta-Sen
- ️Tue Nov 20 2018
- Article
- Published: 20 November 2018
Bariatric Surgery
International Journal of Obesity volume 43, pages 1019–1025 (2019)Cite this article
-
1615 Accesses
-
83 Citations
-
4 Altmetric
Subjects
Abstract
Background/Objectives
Asprosin is a novel fasting-induced glucogenic and orexigenic protein hormone. The clinical function of asprosin in obesity is currently unknown. This study investigated the association between asprosin abundance and the outcome of bariatric surgery.
Subjects/Methods
Patients with body mass index more than 35 kg/m2 were recruited for the Obesity and Clock for Elegant Aging Registry in 2011—2016. Body weight changes, blood sugar, and asprosin were assessed in 117 patients receiving bariatric surgery and 57 non-obese subjects as normal control. Primary outcomes of excess weight loss percentage at 6 months after bariatric surgery were determined at follow-up.
Results
Asprosin levels were significantly higher in obese patients than in non-obese subjects (2360 ± 5094 vs. 307 ± 832 ng/ml, p < 0.0001). Multivariate analyses showed a significant association of asprosin abundance with excess body weight loss percentage at 6 months after surgery (p < 0.0001). After adjusted for age, sex, smoking, HbA1c, cholesterol, and triglyceride, serum asprosin level was the only independent predictor of 6 months excess weight loss percentage after bariatric surgery. Asprosin levels decreased significantly 6 months after bariatric surgery (162.2 ± 169.1 ng/ml). Furthermore, there was no association between asprosin and serum glucose levels in our study.
Conclusion
This study provides novel evidence that higher asprosin concentrations before bariatric surgery were associated with the weight reduction magnitude at 6 months after surgery. Further studies are warranted to investigate whether asprosin has direct functions to modulate body weight regulation in humans after bariatric surgery.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
References
GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13–27.
Weinsier RL, Hunter GR, Heini AF, Goran MI, Sell SM. The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity. Am J Med. 1998;105:145–50.
Sharma AM. Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metab Disord. 2002;26(Suppl 4):S5–7.
Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T. et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes. 2016;40:1310–9.
Wang C-Y, Kim H-H, Hiroi Y, Sawada N, Salomone S, Benjamin LE, et al. Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal. 2009;2:ra11.
Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766–81.
Kang JG, Park C-Y. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J. 2012;36:13–25.
Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf. 2012;11:459–71.
Crujeiras AB, Gomez-Arbelaez D, Zulet MA, Carreira MC, Sajoux I, de Luis D. et al. Plasma FGF21 levels in obese patients undergoing energy-restricted diets or bariatric surgery: a marker of metabolic stress?. Int J Obes. 2017;41:1570–8.
Buchwald H. Impact of bariatric surgery on life expectancy in severely obese patients with diabetes. Ann Surg. 2017;266:e57.
Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56–65.
Wolfe BL, Terry ML. Expectations and outcomes with gastric bypass surgery. Obes Surg. 2006;16:1622–9.
Kim Y, Crookes PF. Complications of bariatric surgery, essentials and controversies in bariatric surgery, Huang CK, IntechOpen. 2014; 81–82.
Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157:1279–91.
Gavrieli A, Panagiotou G, Mantzoros CS. Leptin administration in physiological or pharmacological doses does not alter circulating irisin levels in humans. Int J Obes. 2016;40:1461–3.
Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165:566–79.
Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23:1444–53.
Greenhill C. Liver: asprosin—new hormone involved in hepatic glucose release. Nat Rev Endocrinol. 2016;12:312.
Acara AC, Bolatkale M, Kızıloğlu İ, İbişoğlu E, Can Ç. A novel biochemical marker for predicting the severity of acute coronary syndrome with unstable angina pectoris: Asprosin. Am J Emerg Med. 2017. https://doi.org/10.1016/j.ajem.2017.12.032.
Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2017. https://doi.org/10.1016/j.cca.2017.10.034.
Isaacs M, Brzozowska M, Xu A, Greenfield J, Center J. Effects of bariatric surgery on adipokine profile over 12 months in humans. Obes Res Clin Pract. 2014;8:50.
Ionut V, Burch M, Youdim A, Bergman RN. Gastrointestinal hormones and bariatric surgery‐induced weight loss. Obesity. 2013. http://onlinelibrary.wiley.com/doi/10.1002/oby.20364/full.
Aron-Wisnewsky J, Doré J, Clement K. The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol Hepatol. 2012;9:590–8.
Wang C-Y, Liao JK. A mouse model of diet-induced obesity and insulin resistance. Methods Mol Biol. 2012;821:421–33.
Kotnik P, Knapič E, Kokošar J, Kovač J, Jerala R, Battelino T, et al. Identification of novel alleles associated with insulin resistance in childhood obesity using pooled-DNA genome wide association study approach. Int J Obes. 2017. https://doi.org/10.1038/ijo.2017.293.
Jedrychowski MP, Wrann CD, Paulo JA, Gerber KK, Szpyt J, Robinson MM, et al. Detection and quantitation of circulating human irisin by tandem mass spectrometry. Cell Metab. 2015;22:734–40.
Wang C-Y. Circadian rhythm, exercise, and heart. Acta Cardiol Sin. 2017;33:539–41.
Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science. 2010;330:1349–54.
Acknowledgements
We thank Mei-Hsiu Lin, Hui-Ting Su, Chi-Wen Cheng, and Tsu-Hui Yeh for technical assistance. C-YW received support from the National Health Research Institute (NHRI-EX106-10617SI), National Science Council (105-2628-B-182-009-MY4), and Chang Gung Memorial Hospital (CMRPG3H0131, CMRPG3H0271, and CMRPG3H0841). M-SW received support from Chang Gung Memorial Hospital (CMRPG3E1852-3 and CMRPG3E1892-3). T-SY received support from Chang Gung Memorial Hospital (CMRPG3C311 and CORPG3C0111-2). We thank the members of the OCEAN (Obesity and Clock for Elegant AgiNg) registry.
Author information
Authors and Affiliations
Department of Cardiology, Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taipei, Taiwan
Chao-Yung Wang, Victor Chien-Chia Wu & Ming-Shien Wen
Department of Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan
Tien-An Lin
Department of General Surgery, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taipei, Taiwan
Keng-Hau Liu, Yu-Yin Liu & Ta-Sen Yeh
Department of Trauma and Emergency Surgery, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan
Chien-Hung Liao
Authors
- Chao-Yung Wang
You can also search for this author inPubMed Google Scholar
- Tien-An Lin
You can also search for this author inPubMed Google Scholar
- Keng-Hau Liu
You can also search for this author inPubMed Google Scholar
- Chien-Hung Liao
You can also search for this author inPubMed Google Scholar
- Yu-Yin Liu
You can also search for this author inPubMed Google Scholar
- Victor Chien-Chia Wu
You can also search for this author inPubMed Google Scholar
- Ming-Shien Wen
You can also search for this author inPubMed Google Scholar
- Ta-Sen Yeh
You can also search for this author inPubMed Google Scholar
Corresponding authors
Correspondence to Chao-Yung Wang or Ta-Sen Yeh.
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Wang, CY., Lin, TA., Liu, KH. et al. Serum asprosin levels and bariatric surgery outcomes in obese adults. Int J Obes 43, 1019–1025 (2019). https://doi.org/10.1038/s41366-018-0248-1
Received: 22 February 2018
Revised: 15 September 2018
Accepted: 26 September 2018
Published: 20 November 2018
Issue Date: May 2019
DOI: https://doi.org/10.1038/s41366-018-0248-1